Previous 10 | Next 10 |
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO Canada NewsWire VANCOUVER, May 15, 2019 - SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1 st - - Sierra to hold Analys...
Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER , May 8, 2019 /PRNewswire/ - Sierra Oncology, Inc. ("Sierra Oncology") (Nasdaq: SRRA), a clinical stage drug development c...
Sierra Oncology to Attend Two Investor Conferences in May Canada NewsWire VANCOUVER, May 6, 2019 VANCOUVER , May 6, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patient...
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019 Canada NewsWire VANCOUVER, April 3, 2019 - Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER , April 3, 2019 /...
- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models - VANCOUVER , April 1, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq...
- Dr. Christian Hassig , CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019 - VANCOUVER , March 5, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of pati...
Sierra Oncology (NASDAQ: SRRA ): Q4 GAAP EPS of -$0.19 beats by $0.04. More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER , Feb. 28, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for th...
- Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models - - Late-breaking abstract reporting preclinical efficacy for Cdc7 inhibito...
- "Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston - VANCOUVER , Jan. 23, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancin...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...